Dublin, Ireland - February 26, 2014, Dublin, Ireland - Jazz Pharmaceuticals plc, a specialty biopharmaceutical company, announced that Kathryn Falberg, executive vice president and chief financial officer, has resigned from the company, effective March 9, 2014.
Article continues below
Ms. Falberg will serve as a consultant to Jazz Pharmaceuticals during a transition period. Ms. Falberg was appointed the company Executive Vice President and Chief Financial Officer in March 2012. She served as Senior Vice President and Chief Financial Officer from 2009 to 2012.
From 1995 through 2001, Ms. Falberg was with Amgen, Inc., where she served as Senior Vice President Finance, Strategy and Chief Financial Officer, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer.
From 2001 through 2008, Ms. Falberg was President of Canyon Capital & Consulting, a private investment and consulting firm, where she worked with a number of smaller companies while also serving as a corporate director and audit committee chair for several companies. From February to November 2009, she was Chief Financial Officer and Chief Operating Officer at ARCA biopharma, Inc., a biopharmaceutical company.
Ms. Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles and is a Certified Public Accountant (inactive). Ms. Falberg currently serves on the boards, and is chair of the audit committees, of biopharmaceutical companies Halozyme Therapeutics, Inc. and Medivation, Inc..
Matthew Young, senior vice president of corporate development at Jazz Pharmaceuticals, has been appointed senior vice president and CFO as of the effectiveness of Ms. Falberg's resignation.
Mr. Young joined Jazz Pharmaceuticals in early 2013. Prior to joining Jazz Pharmaceuticals, Mr. Young worked in investment banking for approximately 20 years. His most recent investment banking role was as the Managing Director in Global Healthcare and Co-Head of Life Sciences at Barclays Capital.
Previously, Mr. Young was head of U.S. Life Sciences at Citigroup, and, prior to that, was head of West Coast Healthcare and directed the life sciences coverage effort at Lehman Brothers. He has worked on numerous mergers and acquisitions, corporate finance and other transactions during his career. ■